0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letter |

Contemporary Nationwide Patterns of Self-reported Prostate-Specific Antigen Screening FREE

Jesse D. Sammon, DO1; Daniel Pucheril, MD, MBA1; Mireya Diaz, PhD1; Adam S. Kibel, MD2; Philip W. Kantoff, MD3; Mani Menon, MD1; Quoc-Dien Trinh, MD1,2,4
[+] Author Affiliations
1Vattikuti Urology Institute Center for Outcomes Research, Analytics, and Evaluation, Henry Ford Health System, Detroit, Michigan
2Division of Urologic Surgery, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts
3Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
4Center for Surgery and Public Health, Harvard Medical School, Boston, Massachusetts
JAMA Intern Med. 2014;174(11):1839-1841. doi:10.1001/jamainternmed.2014.4117.
Text Size: A A A
Published online

Routine screening for prostate cancer using prostate-specific antigen (PSA) is a widely contested practice, and recommendations have recently changed dramatically. In October 2011, the US Preventative Services Task Force recommended against screening in any age group,1 yet current nationwide patterns of PSA screening are largely unknown. We sought to elucidate contemporary PSA screening prevalence with a focus on heterogeneity among states and across age groups. We examine data from the 2012 Behavioral Risk Factor Surveillance System (BRFSS).

The BRFSS is the world’s largest continuously conducted health survey, a joint initiative of the Centers for Disease Control and Prevention and US states. Male respondents 50 years or older without a history of prostate cancer or prostate problem who reported PSA testing within the 12 months preceding the 2012 BRFSS survey were considered to have undergone screening. The 2012 survey was conducted between January 2, 2012, and February 12, 2013. Complex-samples logistic regression analysis incorporating age, race and/or ethnicity, education, income, residence location, insurance status, access to regular health care, and marital status was used to estimate an individual’s predicted probability of undergoing PSA screening. Individual probabilities were then normalized to the 2012 BRFSS screened population to derive state-specific estimates of screening prevalence.

In 2012, 114 544 unique responses from men 50 years or older were captured by the BRFSS, a weighted estimate of 46.24 million men, of whom 17.16 million (37.1%) reported undergoing PSA screening. Access to regular health care was most strongly associated with higher rates of screening (odds ratio [OR], 3.00 [95% CI, 2.69-3.34]). Additional predictors included income greater than $75 000 (OR, 1.91 [95% CI, 1.67-2.20]), college education (OR, 1.90 [95% CI, 1.70-2.12]), health insurance (OR, 1.83 [95% CI, 1.60-2.08]), and age 70 to 74 years (OR, 2.53 [95% CI, 2.29-2.79]) (see eTable in the Supplement). After adjustment for covariates, the estimated prevalence of self-reported PSA screening was highest in Hawaii (59.4%) and lowest in New Hampshire (24.5%) (Figure 1). The prevalence of PSA screening was highest in older men aged 65 to 69 years (48.4%) and 70 to 74 years (48.5%). Men aged 50 to 54 years were the least likely to report PSA screening (25.0%) (Figure 2).

Place holder to copy figure label and caption
Figure 1.
Prevalence of Self-reported Prostate-Specific Antigen (PSA) Screening in US Men 50 Years or Older

Data from Behavioral Risk Factor Surveillance System, 2012. Data are adjusted for age (continuously coded), race and/or ethnicity, education level, income, residence location, health insurance, access to regular health care, and marital status.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Age-Specific Prevalence of Self-reported Prostate-Specific Antigen (PSA) Screening in US Men 50 Years or Older

Data from Behavioral Risk Factor Surveillance System, 2012. Data indicate weighted estimates, and error bars, 95% confidence intervals.

Graphic Jump Location

Whereas changes in sampling methodology preclude direct comparison with prior years of the BRFSS, our data show that the effect of previous guidelines recommending against the routine screening of elderly men has been minimal at best.2 Prior work exploring PSA screening trends following earlier US Preventative Services Task Force recommendations against screening in men older than 75 years demonstrated no significant reduction, and yet men aged 75 to 79 years remain the third most likely age group to undergo screening in the year preceding the survey (weighted estimate, 45.7% [95% CI, 43.6%-47.9%]).3 Equally remarkable is the low rate of PSA screening (weighted estimate, 25.0% [95% CI, 23.8%-26.2%]) among men between 50 and 54 years old, for whom screening has previously been recommended by several professional organizations. These findings likely reflect both the considerable disagreement among experts and the conflicting recommendations. Taken together, these results suggest that national guidelines have had limited effect on clinical practice among health care providers.

The degree of heterogeneity in state-by-state PSA screening prevalence is another concerning and surprising study finding. Evidence from the colorectal and breast cancer screening literature suggests that state-by-state and regional variability is expected but not to such a pronounced extent. For example, regional variability in colorectal screening rates is only 7.5%.4 It is alarming that the prevalence of PSA screening can double from one state to the next. Whereas the causes of this heterogeneity may mirror those in mammography, including variability in the availability of large university hospitals, geographic density of providers, levels of insurance coverage, and income,5 the effect of physician preferences on the odds of screening is far more pronounced for PSA, relative to other screening tests.6

Limitations of our study include recall and nonresponse bias. Inaccuracies in self-reported PSA screening have been found to reflect underreporting, when compared with medical record extraction. Also, only individuals with telephones were sampled, exerting an uncertain bias.

Corresponding Author: Quoc-Dien Trinh, MD, Dana-Farber Cancer Institute, Harvard Medical School, 45 Francis St, ASB II-3, Boston, MA 02115 (trinh.qd@gmail.com).

Published Online: September 1, 2014. doi:10.1001/jamainternmed.2014.4117.

Author Contributions: Drs Sammon and Pucheril served as co–first authors, each with equal contribution to the manuscript. Drs Trinh and Sammon had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Sammon, Pucheril, Kibel, Kantoff, Menon, Trinh.

Acquisition, analysis, or interpretation of data: Sammon, Pucheril, Diaz, Trinh.

Drafting of the manuscript: Sammon, Pucheril, Trinh.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Sammon, Diaz, Trinh.

Obtained funding: Menon.

Administrative, technical, or material support: Pucheril, Kantoff, Menon.

Study supervision: Kibel, Trinh.

Conflict of Interest Disclosures: Dr Kibel consults for Sanofi-Aventis, Dendreon, and Myriad Genetics. No other disclosures are reported.

Funding/Support: This work is supported by the Professor Walter Morris-Hale Distinguished Chair in Urologic Oncology at Brigham and Women’s Hospital.

Role of the Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: Akshay Sood, MD, Vattikuti Urology Institute Center for Outcomes Research, Analytics, and Evaluation, Henry Ford Health System; Simon P. Kim, MD, Department of Urology, Yale University; Jim C. Hu, MD, Department of Urology, David Geffen School of Medicine at UCLA; Paul L. Nguyen, MD, Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School; and Maxine Sun, PhD, Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, were instrumental in creating an earlier manuscript draft of this Research Letter. They were not compensated for their contributions.

Moyer  VA; US Preventive Services Task Force.  Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120-134.
PubMed   |  Link to Article
US Preventive Services Task Force.  Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149(3):185-191.
PubMed   |  Link to Article
Scosyrev  E, Wu  G, Golijanin  D, Messing  E.  Prostate-specific antigen testing in older men in the USA: data from the behavioral risk factor surveillance system. BJU Int. 2012;110(10):1485-1490.
PubMed   |  Link to Article
Haas  JS, Fitzmaurice  G, Brawarsky  P,  et al.  Association of regional variation in primary care physicians’ colorectal cancer screening recommendations with individual use of colorectal cancer screening. Prev Chronic Dis. 2007;4(4):A90.
PubMed
Miller  JW, King  JB, Joseph  DA, Richardson  LC; Centers for Disease Control and Prevention (CDC).  Breast cancer screening among adult women—Behavioral Risk Factor Surveillance System, United States, 2010. MMWR Morb Mortal Wkly Rep. 2012;61(suppl):46-50.
PubMed
Jaramillo  E, Tan  A, Yang  L, Kuo  YF, Goodwin  JS.  Variation among primary care physicians in prostate-specific antigen screening of older men. JAMA. 2013;310(15):1622-1624.
PubMed   |  Link to Article

Figures

Place holder to copy figure label and caption
Figure 1.
Prevalence of Self-reported Prostate-Specific Antigen (PSA) Screening in US Men 50 Years or Older

Data from Behavioral Risk Factor Surveillance System, 2012. Data are adjusted for age (continuously coded), race and/or ethnicity, education level, income, residence location, health insurance, access to regular health care, and marital status.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Age-Specific Prevalence of Self-reported Prostate-Specific Antigen (PSA) Screening in US Men 50 Years or Older

Data from Behavioral Risk Factor Surveillance System, 2012. Data indicate weighted estimates, and error bars, 95% confidence intervals.

Graphic Jump Location

Tables

References

Moyer  VA; US Preventive Services Task Force.  Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120-134.
PubMed   |  Link to Article
US Preventive Services Task Force.  Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149(3):185-191.
PubMed   |  Link to Article
Scosyrev  E, Wu  G, Golijanin  D, Messing  E.  Prostate-specific antigen testing in older men in the USA: data from the behavioral risk factor surveillance system. BJU Int. 2012;110(10):1485-1490.
PubMed   |  Link to Article
Haas  JS, Fitzmaurice  G, Brawarsky  P,  et al.  Association of regional variation in primary care physicians’ colorectal cancer screening recommendations with individual use of colorectal cancer screening. Prev Chronic Dis. 2007;4(4):A90.
PubMed
Miller  JW, King  JB, Joseph  DA, Richardson  LC; Centers for Disease Control and Prevention (CDC).  Breast cancer screening among adult women—Behavioral Risk Factor Surveillance System, United States, 2010. MMWR Morb Mortal Wkly Rep. 2012;61(suppl):46-50.
PubMed
Jaramillo  E, Tan  A, Yang  L, Kuo  YF, Goodwin  JS.  Variation among primary care physicians in prostate-specific antigen screening of older men. JAMA. 2013;310(15):1622-1624.
PubMed   |  Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Supplement.

eTable. Complex Samples Logistic Regression Multivariable Analysis of Predictors of PSA Screening in US Men Age 50 Years and Older, BRFSS 2012

Supplemental Content

Some tools below are only available to our subscribers or users with an online account.

1,700 Views
15 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles
Jobs